US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Xencor, Inc.

< Previous 1 2 3 Next >
News headline image
Xencor to Present at the 2026 Cantor Global Healthcare Conference
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Reports Second Quarter 2026 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Reports First Quarter 2026 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Reports Third Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Reports Second Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Reports First Quarter 2025 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Appoints Todd Simpson to Board of Directors
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor to Participate at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Reports Third Quarter 2024 Financial Results
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Announces Upcoming Change to Board of Directors
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Xencor, Inc.
Via Business Wire
Tickers XNCR
News headline image
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
From Xencor, Inc.
Via Business Wire
Tickers XNCR
< Previous 1 2 3 Next >